Subscribe To
GNPX / Genprex signs exclusive license to additional diabetes technology with University of Pittsburgh
Content Topics
Genprex
Signs
Exclusive
License
Additional
Diabetes
Technology
University
Pittsburgh
Stock
GNPX
GNPX News
By Zacks Investment Research
September 4, 2023
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st more_horizontal
By Proactive Investors
July 5, 2023
Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers
Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead dru more_horizontal
By Proactive Investors
June 28, 2023
Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA
Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Dru more_horizontal
By Zacks Investment Research
June 1, 2023
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer. more_horizontal
By Proactive Investors
May 30, 2023
Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancer
Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combi more_horizontal
By Proactive Investors
May 26, 2023
Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting
Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combin more_horizontal
By Proactive Investors
April 19, 2023
Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise
A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the compa more_horizontal
By Proactive Investors
April 18, 2023
Genprex encouraged by latest reports on novel tumor suppressor
Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functio more_horizontal